Information  X 
Enter a valid email address

Urban&Civic Plc (UANC)

  Print      Mail a friend

Wednesday 04 July, 2018

Urban&Civic Plc

Additional Listing

RNS Number : 6274T
Urban&Civic plc
04 July 2018
 

 

4 July 2018 

Urban&Civic plc

Additional listing - scrip dividend shares

 Urban&Civic plc (the "Company") announces that applications have been made for 18,216 ordinary shares to be issued in accordance with the terms of the scrip dividend scheme, at a price of 334 pence per share ("Scrip Dividend Shares"). The Scrip Dividend Shares are to be issued in relation to the interim dividend for the year ending 30 September 2018, payable on 13 July 2018.

An application will be made for the 18,216 Scrip Dividend Shares to be admitted to the standard segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of the London Stock Exchange ("Admission"). Once admitted the Scrip Dividend Shares will rank pari passu with the existing issued ordinary shares of the Company. 

It is expected that Admission will become effective and unconditional dealings in the Scrip Dividend Shares will commence on or around 8.00am on 13 July 2018.

Following Admission, the Company's issued share capital will comprise 145,044,582 ordinary shares with one voting right per share. No shares are held in Treasury. The total number of voting rights in the Company will therefore be 145,044,582.

This figure of 145,044,582 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

Urban&Civic plc

Heather Williams                                   020 7509 5555

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ALSSSUFLLFASEFW

a d v e r t i s e m e n t